Extracorporeal Hemoperfusion as a Potential Therapeutic Option for Critical Accumulation of Rivaroxaban

Blood Purif. 2018;45(1-3):126-128. doi: 10.1159/000484923. Epub 2017 Dec 21.

Authors

Andreas Koertge¹, Reinhold Wasserkort¹, Thomas Wild¹, Steffen Mitzner^{1

2}

Affiliations

¹ Fraunhofer Institute for Cell Therapy and Immunology, Extracorporeal Immunomodulation Unit, Rostock, Germany.
² Division of Nephrology, Centre for Internal Medicine, University Medicine Rostock, Rostock, Germany.

PMID: 29402788
DOI: 10.1159/000484923

No abstract available

Publication types

Letter

MeSH terms

Hemoperfusion / instrumentation*
Hemoperfusion / methods*
Humans
Rivaroxaban / pharmacokinetics*
Rivaroxaban / pharmacology

Substances

Rivaroxaban